VSEE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
VSEE is not a good buy right now for an impatient investor. The stock is still in a clear bearish trend (stacked bearish moving averages) with no Intellectia buy signals today, and fundamentals show revenue growth but sharply weaker profitability and margins. With price sitting just above near-term support, it’s more of a “watch for a bounce confirmation” than an immediate buy.
Trend: Bearish. The moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating sustained downside pressure. Momentum: MACD histogram is slightly positive (0.000812) but positively contracting, suggesting any upside momentum is fading rather than strengthening. RSI: RSI_6 at 22.757 is effectively oversold territory (even though labeled neutral in the feed), which can set up a short-term bounce, but oversold alone is not a reliable buy trigger in a downtrend. Levels: Current price 0.369 is below the pivot (0.395) and close to S1 (0.354). A breakdown below 0.354 increases risk toward S2 (0.329). A credible bullish shift would start with reclaiming 0.395, then targeting 0.436 (R1). Pattern-based odds: Similar-pattern stats show a slightly negative next day expectation (-1.21%) but positive skew over 1 week (+2.72%) and 1 month (+6.66%); that supports a potential bounce thesis, but not a high-conviction entry today.
Intellectia Proprietary Trading Signals
may support a technical bounce if buyers defend the 0.354 support area.
Latest quarter: 2025/Q3. Revenue grew to 3,980,655 (+18.67% YoY), but profitability worsened significantly: Net income fell to -289,745 (-99.46% YoY), EPS to -0.02 (-99.44% YoY), and gross margin declined to 52.08% (-37.27% YoY). This is growth without improving quality of earnings, which weakens the “buy now” case.
No analyst rating or price target change data was provided. Wall Street pros/cons cannot be validated from the dataset. Based on available info only: Pros—revenue growth and a potentially meaningful AI/virtual ICU partnership; Cons—downtrending chart structure and worsening margins/earnings.
